Pharmos Announces Clinical Results From Phase 2a Trial Of Topical Diclofenac NanoEmulsion Cream

Pharmos Corporation (Nasdaq: PARS) announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized, double-blinded, placebo controlled study evaluated the safety and efficacy of the Company’s 3% Diclofenac Diethanolamine NanoEmulsion cream in 104 patients with chronic pain due to osteoarthritis of the knee.

More: continued here

Filed under: Clinical Trials on November 21st, 2008